Faculty

Back to Index
Paul Stephen Aisen, MD
Professor of Neurology
Director, Alzheimer's Therapeutic Research Institute
Neurology
ATRI 9860 Mesa Rim Road Health Sciences Campus San Diego

Overview

Paul Aisen, M.D., has been appointed founding director of USC ATRI. Aisen has been a leading figure in Alzheimer’s disease research for more than two decades, having developed novel methodologies as well as designed and directed many large therapeutic trials. He received his B.A. in biochemistry and molecular biology from Harvard and his medical degree from Columbia. He completed his residency at Case Western Reserve University in Cleveland and Mount Sinai Medical Center in New York, and then fellowship training in rheumatology at New York University. After serving as chief medical resident at Mount Sinai, he began a solo practice in internal medicine and rheumatology in New York. Aisen joined the faculty of Mount Sinai in 1994 and was recruited to Georgetown University in 1999 as a professor of neurology and medicine. That year, he founded the Memory Disorders Program, a clinical and research program for Alzheimer’s disease and related disorders. He continued basic research studies on therapeutic targets and biomarkers and designed and directed multicenter therapeutic trials. He became vice chair of the Department of Neurology at Georgetown in 2004. From 2007 through 2015, he was professor in the Department of Neurosciences at the University of California, San Diego and director of the Alzheimer’s Disease Cooperative Study.

Publications

. Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials Alzheimers Dement. 2018 May 08. View in: PubMed

. Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial JAMA Neurol. 2018 Mar 26. View in: PubMed

. Author response: A phase 3 trial of IV immunoglobulin for Alzheimer disease Neurology. 2018 Jan 16; 90(3):145. View in: PubMed

. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease N Engl J Med. 2018 05 03; 378(18):1691-1703. View in: PubMed

. A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease Alzheimers Dement (N Y). 2018; 4:46-53. View in: PubMed

. J Prev Alzheimers Dis. 2018; 5(3):171-174. View in: PubMed

. Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease Neurobiol Aging. 2017 Dec; 60:92-103. View in: PubMed

. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid ß Alzheimers Dement. 2017 Sep; 13(9):1004-1012. View in: PubMed

. On the path to 2025: understanding the Alzheimer's disease continuum Alzheimers Res Ther. 2017 Aug 09; 9(1):60. View in: PubMed

. Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary Report Alzheimers Dement (N Y). 2017 Jun; 3(2):177-188. View in: PubMed

. Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease BMC Med Genomics. 2017 May 24; 10(Suppl 1):29. View in: PubMed

. A phase 3 trial of IV immunoglobulin for Alzheimer disease Neurology. 2017 May 02; 88(18):1768-1775. View in: PubMed

. Randomized controlled trials in mild cognitive impairment: Sources of variability Neurology. 2017 May 02; 88(18):1751-1758. View in: PubMed

. The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement Alzheimers Dement. 2017 May; 13(5):561-571. View in: PubMed

. Association between tau deposition and antecedent amyloid-ß accumulation rates in normal and early symptomatic individuals Brain. 2017 May 01; 140(5):1499-1512. View in: PubMed

. Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials Alzheimers Dement. 2017 Apr; 13(4):e1-e85. View in: PubMed

. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease J Neuroinflammation. 2017 Jan 03; 14(1):1. View in: PubMed

. Statistical properties of continuous composite scales and implications for drug development J Biopharm Stat. 2017; 27(6):1104-1114. View in: PubMed

. Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons JAMA. 2017 06 13; 317(22):2305-2316. View in: PubMed

. Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment J Alzheimers Dis. 2017; 56(1):229-237. View in: PubMed

. Elevated Brain Amyloid in Cognitively Normal Individuals-Reply JAMA. 2017 10 10; 318(14):1393-1394. View in: PubMed

. Cross-validation of optimized composites for preclinical Alzheimer's disease Alzheimers Dement (N Y). 2017 Jan; 3(1):123-129. View in: PubMed

. The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older Adults J Alzheimers Dis. 2017; 60(2):427-437. View in: PubMed

. EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials J Prev Alzheimers Dis. 2017; 4(2):116-124. View in: PubMed

. Drug development in Alzheimer's disease: the path to 2025 Alzheimers Res Ther. 2016 Sep 20; 8:39. View in: PubMed

. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease Alzheimers Res Ther. 2016 Jun 30; 8:25. View in: PubMed

. Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease Alzheimers Dement (N Y). 2016 Jun; 2(2):131-139. View in: PubMed

. Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults JAMA Neurol. 2016 Jun 01; 73(6):721-32. View in: PubMed

. Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial Neurology. 2016 May 31; 86(22):2071-6. View in: PubMed

. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria Alzheimers Dement. 2016 Mar; 12(3):292-323. View in: PubMed

. The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials J Prev Alzheimers Dis. 2016 Mar; 3(1):8-12. View in: PubMed

. Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia Am J Geriatr Psychiatry. 2016 Feb; 24(2):126-35. View in: PubMed

. Cognitive and functional changes associated with Aß pathology and the progression to mild cognitive impairment Neurobiol Aging. 2016 12; 48:172-181. View in: PubMed

. Longitudinal decline in mild-to-moderate Alzheimer's disease: Analyses of placebo data from clinical trials Alzheimers Dement. 2016 05; 12(5):598-603. View in: PubMed

. Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials Alzheimers Dement. 2016 05; 12(5):631-2. View in: PubMed

. Accelerating rates of cognitive decline and imaging markers associated with ß-amyloid pathology Neurology. 2016 05 17; 86(20):1887-96. View in: PubMed

. Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer's disease BMC Med Genomics. 2016 08 12; 9 Suppl 1:30. View in: PubMed

. CAP--advancing the evaluation of preclinical Alzheimer disease treatments Nat Rev Neurol. 2016 Jan; 12(1):56-61. View in: PubMed

. APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern Alzheimers Dement. 2015 Dec; 11(12):1417-1429. View in: PubMed

. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease Neurology. 2015 Oct 20; 85(16):1383-91. View in: PubMed

. GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP Brain. 2015 Oct; 138(Pt 10):3076-88. View in: PubMed

. The transitional association between ß-amyloid pathology and regional brain atrophy Alzheimers Dement. 2015 Oct; 11(10):1171-9. View in: PubMed

. Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline J Alzheimers Dis. 2015 Sep 24; 48 Suppl 1:S171-91. View in: PubMed

. Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials Alzheimers Dement. 2015 Sep; 11(9):1069-79. View in: PubMed

. Self-rated and informant-rated everyday function in comparison to objective markers of Alzheimer's disease Alzheimers Dement. 2015 Sep; 11(9):1080-9. View in: PubMed

. Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions Lancet Neurol. 2015 Sep; 14(9):926-944. View in: PubMed

. Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 35 years. Alzheimers Dement (N Y). 2015 Sep; 1(2):111-121. View in: PubMed

. The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding Alzheimers Dement. 2015 Jul; 11(7):823-31. View in: PubMed

. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans Alzheimers Dement. 2015 Jul; 11(7):772-91. View in: PubMed

. Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans Alzheimers Dement. 2015 Jul; 11(7):734-9. View in: PubMed

. Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014 Alzheimers Dement. 2015 Jul; 11(7):865-84. View in: PubMed

. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception Alzheimers Dement. 2015 Jun; 11(6):e1-120. View in: PubMed

. Predicting Reduction of Cerebrospinal Fluid ß-Amyloid 42 in Cognitively Healthy Controls JAMA Neurol. 2015 May; 72(5):554-60. View in: PubMed

. Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease Ann Clin Transl Neurol. 2015 May; 2(5):534-47. View in: PubMed

. Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument JAMA Neurol. 2015 Apr; 72(4):446-54. View in: PubMed

. Advances in Alzheimer's disease drug development BMC Med. 2015 Mar 25; 13:62. View in: PubMed

. Brain structure and function as mediators of the effects of amyloid on memory Neurology. 2015 Mar 17; 84(11):1136-44. View in: PubMed

. Protective variant for hippocampal atrophy identified by whole exome sequencing Ann Neurol. 2015 Mar; 77(3):547-52. View in: PubMed

. Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future Expert Rev Neurother. 2015 Jan; 15(1):83-105. View in: PubMed

. Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment Neurobiol Aging. 2015 Jan; 36(1):273-82. View in: PubMed

. Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease J Alzheimers Dis. 2015; 47(1):205-14. View in: PubMed

. Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia J Alzheimers Dis. 2015; 43(3):949-55. View in: PubMed

. Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials Alzheimers Res Ther. 2015; 7(1):39. View in: PubMed

. The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome Front Behav Neurosci. 2015; 9:239. View in: PubMed

. Alzheimer's disease progression by geographical region in a clinical trial setting Alzheimers Res Ther. 2015; 7(1):43. View in: PubMed

. Alzheimers Res Ther. 2015; 7(1):36. View in: PubMed

. Estimating long-term multivariate progression from short-term data Alzheimers Dement. 2014 Oct; 10(5 Suppl):S400-10. View in: PubMed

. 2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease Alzheimers Dement. 2014 Oct; 10(5 Suppl):S430-52. View in: PubMed

. The Alzheimer's disease cooperative study prevention instrument project: longitudinal outcome of behavioral measures as predictors of cognitive decline Dement Geriatr Cogn Dis Extra. 2014 Sep-Dec; 4(3):509-16. View in: PubMed

. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline JAMA Neurol. 2014 Aug; 71(8):961-70. View in: PubMed

. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis Neurology. 2014 Jul 15; 83(3):253-60. View in: PubMed

. Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative Alzheimers Dement. 2014 Jun; 10(3 Suppl):S226-35. View in: PubMed

. Alzheimer's Disease Cooperative Study Prevention Instrument Project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study J Am Geriatr Soc. 2014 May; 62(5):985-8. View in: PubMed

. Clinical trial of an inhibitor of RAGE-Aß interactions in Alzheimer disease Neurology. 2014 Apr 29; 82(17):1536-42. View in: PubMed

. Serum brain-derived neurotrophic factor and the risk for dementia JAMA. 2014 Apr 23-30; 311(16):1684-5. View in: PubMed

. Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020 Biochem Pharmacol. 2014 Apr 15; 88(4):426-49. View in: PubMed

. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014 Mar 19; 6(228):228fs13. View in: PubMed

. Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer's disease Am J Alzheimers Dis Other Demen. 2014 Mar; 29(2):159-65. View in: PubMed

. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease N Engl J Med. 2014 Jan 23; 370(4):311-21. View in: PubMed

. Effect of TTP488 in patients with mild to moderate Alzheimer's disease BMC Neurol. 2014 Jan 15; 14:12. View in: PubMed

. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease N Engl J Med. 2014 04 10; 370(15):1460. View in: PubMed

. Association of plasma and cortical amyloid beta is modulated by APOE e4 status Alzheimers Dement. 2014 Jan; 10(1):e9-e18. View in: PubMed

. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):E4502-9. View in: PubMed

. Detecting When "Quality of Life" Has Been "Enhanced": Estimating Change in Quality of Life Ratings Open J Philos. 2013 Nov 01; 3(4A):24-31. View in: PubMed

. Semagacestat for treatment of Alzheimer's disease N Engl J Med. 2013 Oct 24; 369(17):1661. View in: PubMed

. Focal hemosiderin deposits and ß-amyloid load in the ADNI cohort Alzheimers Dement. 2013 Oct; 9(5 Suppl):S116-23. View in: PubMed

. Developing dementia prevention trials: baseline report of the Home-Based Assessment study Alzheimer Dis Assoc Disord. 2013 Oct-Dec; 27(4):356-62. View in: PubMed

. The effect of subsyndromal symptoms of depression and white matter lesions on disability for individuals with mild cognitive impairment Am J Geriatr Psychiatry. 2013 Sep; 21(9):906-14. View in: PubMed

. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception Alzheimers Dement. 2013 Sep; 9(5):e111-94. View in: PubMed

. Mild cognitive impairment due to Alzheimer disease in the community Ann Neurol. 2013 Aug; 74(2):199-208. View in: PubMed

. A phase 3 trial of semagacestat for treatment of Alzheimer's disease N Engl J Med. 2013 Jul 25; 369(4):341-50. View in: PubMed

. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force Alzheimers Dement. 2013 Jul; 9(4):438-44. View in: PubMed

. Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly Neuropsychology. 2013 Jul; 27(4):391-401. View in: PubMed

. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease Nat Rev Drug Discov. 2013 Apr; 12(4):324. View in: PubMed

. Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study Alzheimer Dis Assoc Disord. 2013 Apr-Jun; 27(2):174-81. View in: PubMed

. Health-related resource use and costs in elderly adults with and without mild cognitive impairment J Am Geriatr Soc. 2013 Mar; 61(3):396-402. View in: PubMed

. Antioxidants for Alzheimer disease-reply JAMA Neurol. 2013 Feb; 70(2):270-1. View in: PubMed

. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers Lancet Neurol. 2013 Feb; 12(2):207-16. View in: PubMed

. Effect of study partner on the conduct of Alzheimer disease clinical trials Neurology. 2013 Jan 15; 80(3):282-8. View in: PubMed

. The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI) Front Aging Neurosci. 2013; 5:11. View in: PubMed

. Early indications of future cognitive decline: stable versus declining controls PLoS One. 2013; 8(9):e74062. View in: PubMed

. Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel PLoS One. 2013; 8(7):e70269. View in: PubMed

. Genome-wide pathway analysis of memory impairment in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks Brain Imaging Behav. 2012 Dec; 6(4):634-48. View in: PubMed

. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network Clin Investig (Lond). 2012 Oct 01; 2(10):975-984. View in: PubMed

. Amyloid deposition, hypometabolism, and longitudinal cognitive decline Ann Neurol. 2012 Oct; 72(4):578-86. View in: PubMed

. CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects Cereb Cortex. 2012 Sep; 22(9):1993-2004. View in: PubMed

. Clinical and biomarker changes in dominantly inherited Alzheimer's disease N Engl J Med. 2012 Aug 30; 367(9):795-804. View in: PubMed

. Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials Arch Neurol. 2012 Jul; 69(7):901-5. View in: PubMed

. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures Arch Neurol. 2012 Jul; 69(7):836-41. View in: PubMed

. Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease J Neural Transm (Vienna). 2012 Jul; 119(7):843-50. View in: PubMed

. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease Alzheimers Dement. 2012 Jul; 8(4):261-71. View in: PubMed

. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease Arch Neurol. 2012 Jul; 69(7):856-67. View in: PubMed

. Amyloid-ß--associated clinical decline occurs only in the presence of elevated P-tau Arch Neurol. 2012 Jun; 69(6):709-13. View in: PubMed

. Considerations in the design of clinical trials for cognitive aging J Gerontol A Biol Sci Med Sci. 2012 Jun; 67(7):766-72. View in: PubMed

. Nonlinear time course of brain volume loss in cognitively normal and impaired elders Neurobiol Aging. 2012 May; 33(5):845-55. View in: PubMed

. Longitudinal stability of subsyndromal symptoms of depression in individuals with mild cognitive impairment: relationship to conversion to dementia after 3 years Int J Geriatr Psychiatry. 2012 Apr; 27(4):355-63. View in: PubMed

. Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans Proc Natl Acad Sci U S A. 2012 Mar 06; 109(10):3985-90. View in: PubMed

. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease Cold Spring Harb Perspect Med. 2012 Mar; 2(3):a006395. View in: PubMed

. Incidence of new-onset seizures in mild to moderate Alzheimer disease Arch Neurol. 2012 Mar; 69(3):368-72. View in: PubMed

. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception Alzheimers Dement. 2012 Feb; 8(1 Suppl):S1-68. View in: PubMed

. Down's syndrome and Alzheimer's disease: towards secondary prevention Nat Rev Drug Discov. 2012 09; 11(9):655-6. View in: PubMed

. Using the Guttman scale to define and estimate measurement error in items over time: the case of cognitive decline and the meaning of "points lost" PLoS One. 2012; 7(2):e30019. View in: PubMed

. Biomarkers for Alzheimer's disease therapeutic trials Prog Neurobiol. 2011 Dec; 95(4):579-93. View in: PubMed

. Clinical trial methodologies for disease-modifying therapeutic approaches Neurobiol Aging. 2011 Dec; 32 Suppl 1:S64-6. View in: PubMed

. Prevention trials in Alzheimer's disease: an EU-US task force report Prog Neurobiol. 2011 Dec; 95(4):594-600. View in: PubMed

. Evidence for ordering of Alzheimer disease biomarkers Arch Neurol. 2011 Dec; 68(12):1526-35. View in: PubMed

. Testing the right target and right drug at the right stage Sci Transl Med. 2011 Nov 30; 3(111):111cm33. View in: PubMed

. Amyloid-ß associated volume loss occurs only in the presence of phospho-tau Ann Neurol. 2011 Oct; 70(4):657-61. View in: PubMed

. Longitudinal change of biomarkers in cognitive decline Arch Neurol. 2011 Oct; 68(10):1257-66. View in: PubMed

. Factors affecting Aß plasma levels and their utility as biomarkers in ADNI Acta Neuropathol. 2011 Oct; 122(4):401-13. View in: PubMed

. Impact of apolipoprotein E4-cerebrospinal fluid ß-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment Alzheimers Dement. 2011 Sep; 7(5):514-20. View in: PubMed

. Q&A: The Alzheimer's Disease Neuroimaging Initiative BMC Med. 2011 Sep 01; 9:101. View in: PubMed

. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch Gen Psychiatry. 2011 Aug; 68(8):853-61. View in: PubMed

. AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials Alzheimers Dement. 2011 Jul; 7(4):e109-17. View in: PubMed

. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease Alzheimer Dis Assoc Disord. 2011 Jul-Sep; 25(3):206-12. View in: PubMed

. Commentary on "Biomarkers in Alzheimer's disease drug development" Can't live without 'em. Alzheimers Dement. 2011 May; 7(3):e48-50. View in: PubMed

. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement. 2011 May; 7(3):280-92. View in: PubMed

. Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition Brain. 2011 May; 134(Pt 5):1479-92. View in: PubMed

. Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease Alzheimer Dis Assoc Disord. 2011 Apr-Jun; 25(2):122-7. View in: PubMed

. Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010 Alzheimers Dement. 2011 Mar; 7(2):127-32. View in: PubMed

. Requiring an amyloid-ß1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials Alzheimers Dement. 2011 Mar; 7(2):245-6; author reply 247-9. View in: PubMed

. Transforming cerebrospinal fluid Aß42 measures into calculated Pittsburgh Compound B units of brain Aß amyloid Alzheimers Dement. 2011 Mar; 7(2):133-41. View in: PubMed

. Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study) Arch Med Sci. 2011 Feb; 7(1):102-11. View in: PubMed

. A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice PLoS One. 2011 Jan 17; 6(1):e16259. View in: PubMed

. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease Alzheimers Res Ther. 2011 Jan 06; 3(1):1. View in: PubMed

. A lead study on oxidative stress-mediated dehydroepiandrosterone formation in serum: the biochemical basis for a diagnosis of Alzheimer's disease J Alzheimers Dis. 2011; 24 Suppl 2:5-16. View in: PubMed

. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial JAMA. 2010 Nov 03; 304(17):1903-11. View in: PubMed

. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease Brain. 2010 Nov; 133(11):3336-48. View in: PubMed

. Dependence as a unifying construct in defining Alzheimer's disease severity Alzheimers Dement. 2010 Nov; 6(6):482-93. View in: PubMed

. Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment Alzheimers Dement. 2010 Sep; 6(5):412-9. View in: PubMed

. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study Neurobiol Aging. 2010 Aug; 31(8):1340-54. View in: PubMed

. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects Neurobiol Aging. 2010 Aug; 31(8):1284-303. View in: PubMed

. Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease Alzheimer Dis Assoc Disord. 2010 Jul-Sep; 24(3):269-77. View in: PubMed

. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease Exp Neurol. 2010 Jun; 223(2):334-46. View in: PubMed

. The Alzheimer's disease neuroimaging initiative: progress report and future plansAlzheimers Dement. 2010 May; 6(3):202-11. e7. View in: PubMed

. Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans Alzheimers Dement. 2010 May; 6(3):239-46. View in: PubMed

. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects Alzheimers Dement. 2010 May; 6(3):230-8. View in: PubMed

. 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI Hum Brain Mapp. 2010 May; 31(5):786-97. View in: PubMed

. Therapeutics for cognitive aging Ann N Y Acad Sci. 2010 Apr; 1191 Suppl 1:E1-15. View in: PubMed

. NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementia Alzheimer Dis Assoc Disord. 2010 Apr-Jun; 24(2):159-64. View in: PubMed

. Developing a national strategy to prevent dementia: Leon Thal Symposium 2009 Alzheimers Dement. 2010 Mar; 6(2):89-97. View in: PubMed

. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease Ann Neurol. 2010 Mar; 67(3):308-16. View in: PubMed

. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol. 2010 Jan; 9(1):119-28. View in: PubMed

. What the CERAD Battery Can Tell Us about Executive Function as a Higher-Order Cognitive Faculty Curr Gerontol Geriatr Res. 2010; 510614. View in: PubMed

. The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome Alzheimer Dis Assoc Disord. 2009 Oct-Dec; 23(4):315-8. View in: PubMed

. MRI substudy participation in Alzheimer disease (AD) clinical trials: baseline comparability of a substudy sample to entire study population Alzheimer Dis Assoc Disord. 2009 Oct-Dec; 23(4):333-6. View in: PubMed

. No cross-sectional influence of APOE epsilon4 dose on clinical tests in Alzheimer's disease Neurobiol Aging. 2009 Aug; 30(8):1327-8. View in: PubMed

. Alzheimer's disease therapeutic research: the path forward Alzheimers Res Ther. 2009 Jul 09; 1(1):2. View in: PubMed

. Can lithium or valproate untie tangles in Alzheimer's disease? J Clin Psychiatry. 2009 Jun; 70(6):919-21. View in: PubMed

. The net effect of alternative allocation ratios on recruitment time and trial cost Clin Trials. 2009 Apr; 6(2):126-32. View in: PubMed

. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects Ann Neurol. 2009 Apr; 65(4):403-13. View in: PubMed

. A roadmap for the prevention of dementia II: Leon Thal Symposium 2008 Alzheimers Dement. 2009 Mar; 5(2):85-92. View in: PubMed

. Commentary on "a roadmap for the prevention of dementia IILeon Thal Symposium 2008. " Facilitating Alzheimer's disease drug development in the United States. Alzheimers Dement. 2009 Mar; 5(2):125-7. View in: PubMed

. Recent developments in Alzheimer's disease therapeutics BMC Med. 2009 Feb 19; 7:7. View in: PubMed

. Levels of soluble and insoluble tau reflect overall status of tau phosphorylation in vivo Neurosci Lett. 2009 Jan 23; 450(1):51-5. View in: PubMed

. Agreement in cognitive and clinical assessments in Alzheimer's disease Dement Geriatr Cogn Disord. 2009; 27(4):344-52. View in: PubMed

. Methodological issues in primary prevention trials for neurodegenerative dementia J Alzheimers Dis. 2009; 16(2):235-70. View in: PubMed

. Applications of neuroimaging to disease-modification trials in Alzheimer's disease Behav Neurol. 2009; 21(1):129-36. View in: PubMed

. Plasma urate and progression of mild cognitive impairment Neurodegener Dis. 2009; 6(1-2):23-8. View in: PubMed

. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial JAMA. 2008 Oct 15; 300(15):1774-83. View in: PubMed

. Amyloid-based therapeutics: findings translated into novel treatments CNS Spectr. 2008 Oct; 13(10 Suppl 16):36-8. View in: PubMed

. Protection of red blood cell acetylcholinesterase by oral huperzine A against ex vivo soman exposure: next generation prophylaxis and sequestering of acetylcholinesterase over butyrylcholinesterase Chem Biol Interact. 2008 Sep 25; 175(1-3):380-6. View in: PubMed

. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease Arch Neurol. 2008 Aug; 65(8):1031-8. View in: PubMed

. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study Lancet. 2008 Jul 19; 372(9634):207-15. View in: PubMed

. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model Brain Res. 2008 Jun 24; 1216:92-103. View in: PubMed

. Tarenflurbil: a shot on goal Lancet Neurol. 2008 Jun; 7(6):468-9. View in: PubMed

. Treatment for MCI: is the evidence sufficient? Neurology. 2008 May 27; 70(22):2020-1. View in: PubMed

. A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium Alzheimers Dement. 2008 May; 4(3):156-63. View in: PubMed

. Beta-site amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of endogenous amyloid beta in wild-type and transgenic mice in vivo Neurosci Lett. 2008 Apr 25; 435(3):186-9. View in: PubMed

. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease J Pharmacol Exp Ther. 2008 Apr; 325(1):146-53. View in: PubMed

. An update on huperzine A as a treatment for Alzheimer's disease Expert Opin Investig Drugs. 2008 Feb; 17(2):209-15. View in: PubMed

. Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial Curr Alzheimer Res. 2008 Feb; 5(1):73-82. View in: PubMed

. The inflammatory hypothesis of Alzheimer disease: dead or alive? Alzheimer Dis Assoc Disord. 2008 Jan-Mar; 22(1):4-5. View in: PubMed

. An aspirin a day for Alzheimer's disease? Lancet Neurol. 2008 Jan; 7(1):20-1. View in: PubMed

. Leon Thal and the therapeutic age of Alzheimer's disease Alzheimers Dement. 2008 Jan; 4(1 Suppl 1):S4-6. View in: PubMed

. Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration Eur J Neurosci. 2007 Nov; 26(9):2458-68. View in: PubMed

. Commentary on "The Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, 2006"--an appraisal. Alzheimers Dement. 2007 Oct; 3(4):446-8. View in: PubMed

. Alzhemed: a potential treatment for Alzheimer's disease Curr Alzheimer Res. 2007 Sep; 4(4):473-8. View in: PubMed

. Antibody against C-terminal Abeta selectively elevates plasma Abeta Neuroreport. 2007 Feb 12; 18(3):293-6. View in: PubMed

. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage J Mol Neurosci. 2007; 31(2):165-70. View in: PubMed

. A simple method to rule out dementia with temporal orientation Alzheimers Dement. 2007 Jan; 3(1):28-32. View in: PubMed

. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice J Neurochem. 2006 Dec; 99(6):1555-63. View in: PubMed

. ADCS Prevention Instrument Project: overview and initial results Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S109-23. View in: PubMed

. Commentary on "Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials" Alzheimers Dement. 2006 Oct; 2(4):272-4. View in: PubMed

. Independent contributions of neural and "higher-order" deficits to symptoms in Alzheimer's disease: a latent variable modeling approach Alzheimers Dement. 2006 Oct; 2(4):303-13. View in: PubMed

. ADCS Prevention Instrument Project: the Mail-In Cognitive Function Screening Instrument (MCFSI) Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S170-8. View in: PubMed

. Development of a disease-modifying treatment for Alzheimer's disease: Alzhemed Alzheimers Dement. 2006 Jul; 2(3):153-4. View in: PubMed

. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman Chem Biol Interact. 2005 Dec 15; 157-158:239-46. View in: PubMed

. Can rofecoxib delay a diagnosis of Alzheimer's disease in patients with mild cognitive impairment? Nat Clin Pract Neurol. 2005 Nov; 1(1):20-1. View in: PubMed

. One-trial 10-item free-recall performance in Taiwanese elderly and near-elderly: A potential screen for cognitive decline Am J Alzheimers Dis Other Demen. 2005 Jul-Aug; 20(4):239-47. View in: PubMed

. An Abeta sequestration approach using non-antibody Abeta binding agents Curr Alzheimer Res. 2005 Apr; 2(2):265-8. View in: PubMed

. Pharmacologic treatment options in Alzheimer's disease: optimizing disease management J Am Acad Nurse Pract. 2005 Mar; Suppl:5-7. View in: PubMed

. The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors CNS Drugs. 2005; 19(12):989-96. View in: PubMed

. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP) CNS Drug Rev. 2005; 11(4):353-68. View in: PubMed

. Benchmarking a test of temporal orientation with data from american and taiwanese persons with Alzheimer's disease and american normal elderly Neuroepidemiology. 2005; 24(1-2):110-6. View in: PubMed

. Inflammatory processes and Alzheimer's disease Expert Rev Neurother. 2004 Sep; 4(5):793-8. View in: PubMed

. Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant Biochem Biophys Res Commun. 2004 Jul 02; 319(3):733-7. View in: PubMed

. Georgetown University School of Medicine Acad Med. 2004 Jul; 79(7 Suppl):S45-50. View in: PubMed

. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials Arch Neurol. 2004 Jan; 61(1):59-66. View in: PubMed

. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial JAMA. 2003 Jun 04; 289(21):2819-26. View in: PubMed

. NSAIDs and hypertension Arch Intern Med. 2003 May 12; 163(9):1115; author reply 1115-6. View in: PubMed

. A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease Am J Geriatr Psychiatry. 2003 Mar-Apr; 11(2):246-9. View in: PubMed

. Anti-inflammatory agents in Alzheimer's disease Curr Neurol Neurosci Rep. 2002 Sep; 2(5):405-9. View in: PubMed

. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease Lancet Neurol. 2002 Sep; 1(5):279-84. View in: PubMed

. Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology Neurobiol Aging. 2002 May-Jun; 23(3):327-34. View in: PubMed

. Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease J Pain Symptom Manage. 2002 Apr; 23(4 Suppl):S35-40. View in: PubMed

. Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2 Acta Neuropathol. 2002 Feb; 103(2):157-62. View in: PubMed

. Informatics and Geriatric Psychiatry Am J Geriatr Psychiatry. 1996 Spring; 4(2):140-151. View in: PubMed

. Determinants of Length of Stay in Geropsychiatry Am J Geriatr Psychiatry. 1994 Spring; 2(2):165-168. View in: PubMed

. Trazodone for Behavioral Disturbance in Alzheimer's Disease Am J Geriatr Psychiatry. 1993 Autumn; 1(4):349-350. View in: PubMed

. Response to Combination Cholinergic/Noradrenergic Treatments in a Patient With Alzheimer's Disease Am J Geriatr Psychiatry. 1993 Summer; 1(3):244-248. View in: PubMed

Powered bySC CTSI